Société de Dermatologie Française
14
1
1
9
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
7.1%
1 terminated/withdrawn out of 14 trials
90.0%
+3.5% vs industry average
21%
3 trials in Phase 3/4
0%
0 of 9 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
Origin and Function of Eosinophilic Polynuclear During DRESS Syndrome
Role: collaborator
Evaluation of Fluid Retention Due to Superpotent Topical Corticosteroid
Role: collaborator
Research of Prognostic Factors Associated With Healing of Venous Leg Ulcers
Role: collaborator
Implication of Human Papillomavirus (HPV) in Lichen Physiopathology in Human (HPVLichen)
Role: collaborator
Assessing the Long Term Effectiveness and Safety of Systemic Treatments in Cutaneous Psoriasis
Role: collaborator
Expression of IL4 Induced Gene 1 in Patients With Cutaneous Melanoma: Value in Prognosis and/or in Predictive Response to Immune Checkpoint Inhibitors
Role: collaborator
Characterization of NK Cells Under First Line Advanced Therapy Either as Curative Therapy for Metastatic Melanoma or as Adjuvant Therapy for High-risk of Recurrence
Role: collaborator
Borrelia Species in Cutaneous Lyme Borreliosis
Role: collaborator
Assessing the Long Term Effectiveness and Safety of Biotherapies in the Treatment of Cutaneous Psoriasis
Role: collaborator
Assessment of the Clinic-pathological Correlation of Basal Cell Carcinoma
Role: collaborator
Interest of Topical Spironolactone's Administration to Prevent Corticoid-induced Epidermal Atrophy
Role: collaborator
Interest of a Systematic Biopsy for Hard-to-heal Leg Ulcers
Role: collaborator
Short Course of Amoxicillin for Erysipelas
Role: collaborator
Maggot Therapy for Wound Debridement
Role: collaborator
All 14 trials loaded